TY - JOUR
T1 - Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration
AU - Rosso, Raffaella
AU - Di Biagio, Antonio
AU - Dentone, Chiara
AU - Gattinara, Guido Castelli
AU - Martino, Alessandra Maria
AU - Viganò, Alessandra
AU - Merlo, Marzia
AU - Giaquinto, Carlo
AU - Rampon, Osvalda
AU - Bassetti, Matteo
AU - Gatti, Giorgio
AU - Viscoli, Claudio
PY - 2006/6
Y1 - 2006/6
N2 - Objectives: Lopinavir/ritonavir is approved for treatment of HIV-infected children at a dosage regimen of 230/57.5 mg/m2 twice daily. However, once daily administration could increase convenience and patient adherence. Our study aimed at evaluating whether inhibitory concentrations are maintained in plasma following administration of lopinavir/ritonavir once daily. Patients and methods: Lopinavir/ritonavir was administered at the standard twice daily regimen to 21 HIV-infected children, as a component of their antiretroviral treatment. Following at least 1 month of administration, seven patients received a dose of 460/115 mg/m2 once daily for three consecutive days. After the third dose of once daily administration, blood samples were drawn at the following times: 0 (pre-dose), 1, 2 and 4 h following administration. The pre-dose (Cmin) and the peak (Cmax) concentrations were compared with the values obtained following twice daily administration in all the study patients. Results: Median (interquartile range) Cmin with the once daily regimen was 1.59 (0.77-6.85) mg/L versus 7.90 (5.45-9.77) mg/L with the twice daily regimen (P <0.05). Cmin was considered inhibitory for wild-type virus (>1.0 mg/L) in four out of seven patients. Cmax did not differ significantly between the once daily and twice daily regimens. Conclusions: Our small pilot study suggests that lopinavir/ritonavir once daily may be a suitable regimen for antiretroviral-naive children. However, due to the high interindividual variability and low concentrations in some patients, therapeutic drug monitoring may be necessary to ensure that concentrations are adequate to inhibit viral replication. A formal clinical study of lopinavir/ritonavir once daily in treatment-naive children is warranted.
AB - Objectives: Lopinavir/ritonavir is approved for treatment of HIV-infected children at a dosage regimen of 230/57.5 mg/m2 twice daily. However, once daily administration could increase convenience and patient adherence. Our study aimed at evaluating whether inhibitory concentrations are maintained in plasma following administration of lopinavir/ritonavir once daily. Patients and methods: Lopinavir/ritonavir was administered at the standard twice daily regimen to 21 HIV-infected children, as a component of their antiretroviral treatment. Following at least 1 month of administration, seven patients received a dose of 460/115 mg/m2 once daily for three consecutive days. After the third dose of once daily administration, blood samples were drawn at the following times: 0 (pre-dose), 1, 2 and 4 h following administration. The pre-dose (Cmin) and the peak (Cmax) concentrations were compared with the values obtained following twice daily administration in all the study patients. Results: Median (interquartile range) Cmin with the once daily regimen was 1.59 (0.77-6.85) mg/L versus 7.90 (5.45-9.77) mg/L with the twice daily regimen (P <0.05). Cmin was considered inhibitory for wild-type virus (>1.0 mg/L) in four out of seven patients. Cmax did not differ significantly between the once daily and twice daily regimens. Conclusions: Our small pilot study suggests that lopinavir/ritonavir once daily may be a suitable regimen for antiretroviral-naive children. However, due to the high interindividual variability and low concentrations in some patients, therapeutic drug monitoring may be necessary to ensure that concentrations are adequate to inhibit viral replication. A formal clinical study of lopinavir/ritonavir once daily in treatment-naive children is warranted.
KW - Pharmacokinetics
KW - Protease inhibitors
KW - Therapeutic drug monitoring
UR - http://www.scopus.com/inward/record.url?scp=33749174135&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749174135&partnerID=8YFLogxK
U2 - 10.1093/jac/dkl136
DO - 10.1093/jac/dkl136
M3 - Article
C2 - 16606636
AN - SCOPUS:33749174135
VL - 57
SP - 1168
EP - 1171
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
SN - 0305-7453
IS - 6
ER -